Jun 14, 2022 4:15pm EDT 180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytren’s Disease
May 31, 2022 8:30am EDT 180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytren’s Disease
May 02, 2022 8:00am EDT REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
Apr 29, 2022 6:32pm EDT 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytren’s Disease Study Results in The Lancet Rheumatology
Jan 31, 2022 8:00am EST 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
Dec 28, 2021 11:00am EST 180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022
Dec 15, 2021 8:15am EST 180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases
Dec 06, 2021 8:15am EST 180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Results